ISRCTN38408594已完成未知
A one year open label assessment of the use of nabilone in the treatment of chronic neuropathic pain
Cambridge Laboratories Ltd (UK)0 个研究点目标入组 90 人开始时间: 2007年9月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Patients with chronic neuropathic pain who have previously participated in the trial entitled: 'A randomised, crossover, double blind comparison of the analgesic effect and patient tolerability of nabilone and dihydrocodeine in chronic neuropathic pain' (see ISRCTN15330757) may enter this study. As such, patients will already have satisfied criteria for the diagnosis of chronic neuropathic pain.
排除标准
- •Patients may not enter the study if they have a history of any of the following conditions:
- •1. Epilepsy
- •2. Liver disease
- •3. Psychosis
- •4. Bipolar disorder
- •5. Substance misuse
- •6. Renal failure
- •7. Adverse reactions to nabilone
- •8. Pregnant women, lactating women or women of childbearing potential not using effective methods of contraception
- •9. Patients involved in ongoing legal action against a third party in which financial compensation is being sought for personal injury alleged to be the cause of the presenting condition
- •Excluded medication:
- •Patients may not take the following medications during the study:
- •1. Antipsychotic drugs
- •2. Benzodiazepine drugs (excepting stable doses of night-time sedatives)
- •3. Monoamine oxidase inhibitors
- •Patients taking cannabinoid preparations of any kind may not be included in the study.
研究者
相似试验
尚未招募
2 期
Studying the effect of Navel filling with medicated oil in relieving symptoms of premenstrual syndromeCTRI/2024/06/069640Priyanka Rajkumar Bhosale
进行中（未招募）
1 期
Phase II, open-label, non-randomized study of nab-paclitaxel for the neoadjuvant treatment of patients with stage II and III luminal breast cancer.eoadjuvant tratment of patients with stage II - III luminal brest cancerMedDRA version: 14.0 Level: PT Classification code 10057654 Term: Breast cancer female System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004476-10-ESFundación Grupo Español de Investigación en Cáncer de Mama (Fundación GEICAM)78
进行中（未招募）
不适用
An Open Label Phase II Study on the Use of Panobinostat in Combination with Bortezomib and Dexamethasone as Induction in Multiple Myeloma Patients Candidate to High-Dose TherapyMultiple Myeloma patients candidate to high-dose therapyMedDRA version: 14.1Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005847-29-ITOSPEDALE POLICLINICO S. MATTEO
进行中（未招募）
1 期
Study to evaluate the impact of VCN-01 on the overall survival of patients with advanced pancreatic cancer treated with standard therapy.Metastatic Pancreatic CancerMedDRA version: 21.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864EUCTR2022-000897-24-DETheriva Biologics, S.L.92
进行中（未招募）
不适用
An Efficacy and 2-year Safety Study of Rosuvastatin in Children and Adolescents (aged from 6 to less than 18 years) with Familial (inherited) Hypercholesterolaemia (high level of cholesterol in blood)EUCTR2009-016492-29-Outside-EU/EEAAstraZeneca AB200